FAQ
HalioDx has its GCP laboratory in Marseille, France and two CLIA laboratories : Marseille France and Richmond, Virginia, USA.
HalioDx has developed pharma services for exploratory biomarker testing, Clinical trial assay and CDx developments for all phases of a clinical trial. HalioDx offers testing compliant with GCP (Good Clinical Practice) or GCLP (Good Clinical and Laboratory Practice) requirements for patient testing.
HalioDx can organize shipment of patient samples from recruiting centers if needed.
HalioDx offers single IHC testing on Frozen Samples and FFPE samples.
HalioDx does not do Fluorescence IHC testing but has developed a multiplex IHC technology, Brightplex®, which can combine up-to 7 biomarkers on 1 FFPE slide.
HalioDx can use protocol to transfer it to its lab. However, some development might be required.
HalioDx has developed pharma services for exploratory biomarker testing, Clinical trial assay and CDx developments for all phases of a clinical trial. Samples and testing traceability are compliant.
HalioDx has an expert team for bioinformatics and biostatistics.
HalioDx offers testing for RNA expression and DNA sequencing.
RNA and DNA can be extracted from FFPE tissues or frozen tissues.
HalioDx is doing testing mainly on human tissues. Only Molecular testing can be performed on mice and/or other animals.
IHC testing can be performed only on humanized Mice/ and or other animals.
If your question(s) is/are not included in the list above, please contact us Contact us
Resources on our Biopharma services
#poster | Jun. 2020
Unravelling the mystery of cancer-associated fibroblast (CAF) populations in the tumor microenvironment by a fully automated sequential chromogenic multiplex assay
AACR2020 Abstract # 5970
#poster | Jun. 2020
Immunoscore workflow enhanced by Artificial Intelligence
AACR2020 Poster # 870
#video | May. 2020
Webinar: Capturing the Complexity of the Tumor Microenvironment | Jérôme Galon, PhD & Jacques Fieschi, PhD
#poster | Dec. 2019
Poster presented at SITC 2019
Immunogram to decipher PD1/L1 ICI resistance: a proof of concept in advanced Non-small cell lung cancer patients of the PIONeeR Project.
#video | Nov. 2019
Webinar: Evaluating Biomarkers During Clinical Trials for Immunotherapies. A Case Study on the Pioneer Project
#poster | Nov. 2019
Poster presented at ESMO 2019 by Transgene
In the Phase Ib/II trial of TG4001, HalioDx Immunoscore®, Immunosign® and others clinical research service have been performed to assess Immune contexture of patients.
#poster | Nov. 2019
Poster presented at SITC 2019
Tumor Infiltrating Lymphocytes (TILs) in triple-negative breast cancer: High Immunoscore is associated with pathological CR in patients receiving neoadjuvant chemotherapy.
#poster | Nov. 2019
Poster presented at ESMO 2019
High Immunoscore® is associated with good response to neo-adjuvant chemotherapy and prolonged survival in advanced Head and Neck cancer patients.
#poster | Nov. 2019
Poster presented at SITC 2019
Unveilling tumor-associated macrophages (TAMs) heterogeneity and plasticity by a fully automated sequential chromogenic multiplex assay.
#poster | Nov. 2019
Poster presented at SITC 2019
Cancer Immunogram: combining multi-parameter approach and machine learning to capture the complexity of tumor immune contexture.
#video | Sep. 2019
Webinar Biomarker Evaluation for CAR T-Cell Therapy: Impact on Drug Development
#publication | Aug. 2019
Angell HK, Bruni D, Barrett JC et al.
The Immunoscore: Colon Cancer and Beyond.
Clin Cancer Res.
#publication | Jul. 2019
Mascaux C, Angelova M, Vasaturo A et al.
Immune evasion before tumour invasion in early lung squamous carcinogenesis.
Nature
#video | Jul. 2019
HalioDX is part of the COLOSSUS project by performing Immunoscore and help stratification of difficult to treat mCRC patients with a final objective to Improve their management and treatment
#video | Jun. 2019
Webinar on Brightplex®: Combining the power of multiplexing & the ease of chromogenic IHC to assess complex immune phenotype
#video | Jun. 2019
Jérôme Galon, winner for the European Inventor Award 2019 for Immunoscore®
#publication | May. 2019
Galon J & Bruni D
Tumor Immunology and Tumor Evolution: Intertwined Histories
Immunity
#publication | May. 2019
Pages F, Andre T, Taieb J et al.
Validation of the Immunoscore prognostic value in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR)
Journal of Clinical Oncology
#video | Apr. 2019
Immunogram Clinical Seminar (Atlanta, April 2019) | Jérôme Galon, PhD
#video | Apr. 2019
Immunogram Clinical Seminar (Atlanta, April 2019) | Jacques Fieschi, PhD
#poster | Apr. 2019
Poster presented at AACR 2019
Combining multimodal biomarkers as an immunogram to guide immunotherapy use: A Proof of Concept
#poster | Apr. 2019
Poster presented at AACR 2019 by Lytix biopharma
A phase I study of the oncolytic peptide LTX-315 generates de novo T-cell responses and clinical benefit in patients with advanced melanoma
#poster | Apr. 2019
Poster presented at AACR 2019 by Lytix biopharma
A phase I study of the oncolytic peptide LTX-315 generates de novo T-cell responses and clinical benefits in patients with advanced sarcoma
#poster | Apr. 2019
Poster presented at AACR 2019
Validation of Brightplex®, a multiplex IHC solution for immune cell phenotyping of the tumor microenvironment
#publication | Mar. 2019
Zeitoun G, Sissy CE, Kirilovsky A et al.
The Immunoscore in the Clinical Practice of Patients with Colon and Rectal Cancers.
Chirurgia (Bucur).
#brochure | Mar. 2019
Brochure Clinical Research
HalioDx Biopharma Services
#publication | Mar. 2019
Galon J & Bruni D
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies.
Nat Rev Drug Discov.
#poster | Nov. 2018
Poster presented at SITC 2018
Myeloid-derived suppressor cells (MDSC) assessment using an automated sequential chromogenic multiplex assay (Brightplex®)
#publication | Oct. 2018
Angelova M, Mlecnik B, Vasaturo A et al.
Evolution of Metastases in Space and Time under Immune Selection.
Cell
#poster | Oct. 2018
Poster presented at the CRI-CIMT-EATI-AACR 2018
T cell exhaustion assessment using an automated sequential chromogenic multiplex assay (Brightplex®)
#poster | Jun. 2018
Poster presented at ASCO 2018 by Lytix biopharma
A Phase I/II study of the oncolytic peptide LTX-315 combined with checkpoint inhibition generates de novo T-cell responses and clinical benefit in patients with advanced solid tumors
#publication | Dec. 2017
Fridman WH, Zitvogel L, Sautès-Fridman C, Kroemer G
The immune contexture in cancer prognosis and treatment.
Nat Rev Clin Oncol.
#poster | Nov. 2017
Poster presented at SITC 2017 by Lytix biopharma
LTX-315, a first in class oncolytic peptide, reshapes the tumor microenvironment in the patients with advanced metastatic tumors: Results from an ongoing study
#poster | Sep. 2017
Poster presented at NSH 2017
A multiplex immunohistochemistry assay for immune cells profiling on whole FFPE tumor tissue sections
#poster | Jun. 2017
Poster presented at ASCO 2017 by Kite Pharma
#poster | Jun. 2017
Poster presented at ASCO 2017 by Lytix biopharma
LTX-315, a first in class oncolytic peptide reshapes the tumor microenvironment inducing a local and systemic effect in metastatic tumors: Results from an ongoing study
#publication | Feb. 2016
Mlecnik B, Bindea G, Kirilovsky A et al.
The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis.
Sci Transl Med.
#publication | Jun. 2015
Berghoff AS, Fuchs E, Ricken G et al.
Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases.
Oncoimmunology
#publication | Oct. 2013
Bindea G, Mlecnik B, Tosolini M et al.
Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.
Immunity
#publication | Jul. 2013
Galon J, Angell HK, Bedognetti D, Marincola FM
The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures.
Immunity
#publication | Mar. 2012
Fridman WH, Pagès F, Sautès-Fridman C, Galon J.
The immune contexture in human tumours: impact on clinical outcome.
Nat Rev Cancer.